GGHC
TSHA icon

Gilder Gagnon Howe & Co’s Taysha Gene Therapies TSHA Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-37,578
Closed -$700K – 432
2021
Q3 		$700K Sell
37,578
-62
-0.2% -$1.18K ﹤0.01% 336
2021
Q2 		$798K Sell
37,640
-184
-0.5% -$4.24K ﹤0.01% 340
2021
Q1 		$768K Sell
37,824
-3,179
-8% -$86.1K ﹤0.01% 307
2020
Q4 		$1.09M Sell
41,003
-2,407
-6% -$51.9K 0.01% 265
2020
Q3 		$972K Buy
+43,410
New +$1.02M 0.01% 262

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Gilder Gagnon Howe & Co's TSHA Position: Q4 2021 in Review

Gilder Gagnon Howe & Co sold out of Taysha Gene Therapies (TSHA) in Q4 2021, closing a stake of 37,578 shares — an estimated $700K sold.

Gilder Gagnon Howe & Co first reported a position in TSHA in Q3 2020 and held it in 5 quarters. The position peaked at $1.09M in Q4 2020. 65 funds tracked by Wall St. Rank hold TSHA as of Q4 2021.

  • Gilder Gagnon Howe & Co reported no remaining Taysha Gene Therapies position as of Q4 2021 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 37,578 Taysha Gene Therapies shares in Q4 2021, an estimated $700K.
  • Gilder Gagnon Howe & Co first reported a position in Taysha Gene Therapies in Q3 2020 and held it in 5 quarters.
  • Gilder Gagnon Howe & Co's Taysha Gene Therapies position peaked at $1.09M in Q4 2020.
  • 65 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2021.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2021, filed 14 Feb 2022.